These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 28302541)

  • 21. Investigation of excipients impact on polysorbate 80 degradation in biopharmaceutical formulation buffers.
    Bai L; Zhang Y; Zhang C; Lu Y; Li Z; Huang G; Meng B
    J Pharm Biomed Anal; 2023 Sep; 233():115496. PubMed ID: 37285658
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Characterization of Polysorbate.
    Zhang S; Xiao H; Li N
    Curr Protoc; 2022 Jul; 2(7):e489. PubMed ID: 35857882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitation of low concentrations of polysorbates 80 in protein formulations by Coomassie brilliant blue.
    Cheng Y; Liu Y; Wei H; Sun R; Tian Z; Zheng X
    Anal Biochem; 2019 May; 573():67-72. PubMed ID: 30853377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Rapid High-Sensitivity Reversed-Phase Ultra High Performance Liquid Chromatography Mass Spectrometry Method for Assessing Polysorbate 20 Degradation in Protein Therapeutics.
    Cheng Y; Hu M; Zamiri C; Carcelen T; Demeule B; Tomlinson A; Gu J; Yigzaw Y; Kalo M; Yu XC
    J Pharm Sci; 2019 Sep; 108(9):2880-2886. PubMed ID: 31054888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of pharmaceutical impurities in formulated dosage forms.
    Pan C; Liu F; Motto M
    J Pharm Sci; 2011 Apr; 100(4):1228-59. PubMed ID: 24081463
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous quantification of polysorbate 20 and poloxamer 188 in biopharmaceutical formulations using evaporative light scattering detection.
    Paschen CA; Klemm D; Graf T; Kopf R; Pinto C; Müller C; Bell CH; Pfaff J
    J Pharm Biomed Anal; 2021 Jan; 192():113640. PubMed ID: 33002754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elemental Impurities in Pharmaceutical Excipients.
    Li G; Schoneker D; Ulman KL; Sturm JJ; Thackery LM; Kauffman JF
    J Pharm Sci; 2015 Dec; 104(12):4197-4206. PubMed ID: 26398581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Degradation of polysorbates 20 and 80: studies on thermal autoxidation and hydrolysis.
    Kishore RS; Pappenberger A; Dauphin IB; Ross A; Buergi B; Staempfli A; Mahler HC
    J Pharm Sci; 2011 Feb; 100(2):721-31. PubMed ID: 20803573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, characterization and assessment of suitability of trehalose fatty acid esters as alternatives for polysorbates in protein formulation.
    Schiefelbein L; Keller M; Weissmann F; Luber M; Bracher F; Friess W
    Eur J Pharm Biopharm; 2010 Nov; 76(3):342-50. PubMed ID: 20816956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-excipient compatibility screening--role of thermoanalytical and spectroscopic techniques.
    Chadha R; Bhandari S
    J Pharm Biomed Anal; 2014 Jan; 87():82-97. PubMed ID: 23845418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
    Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
    J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Industry Perspective on the use and Characterization of Polysorbates for Biopharmaceutical Products Part 1: Survey Report on Current State and Common Practices for Handling and Control of Polysorbates.
    Wuchner K; Yi L; Chery C; Nikels F; Junge F; Crotts G; Rinaldi G; Starkey JA; Bechtold-Peters K; Shuman M; Leiss M; Jahn M; Garidel P; de Ruiter R; Richer SM; Cao S; Peuker S; Huille S; Wang T; Le Brun V
    J Pharm Sci; 2022 May; 111(5):1280-1291. PubMed ID: 35192858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acidic and alkaline hydrolysis of polysorbates under aqueous conditions: Towards understanding polysorbate degradation in biopharmaceutical formulations.
    Dwivedi M; Buske J; Haemmerling F; Blech M; Garidel P
    Eur J Pharm Sci; 2020 Mar; 144():105211. PubMed ID: 31931121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Elemental Impurities Excipient Database: A Viable Tool for ICH Q3D Drug Product Risk Assessment.
    Boetzel R; Ceszlak A; Day C; Drumm P; Gil Bejar J; Glennon J; Harris L; Heghes CI; Horga R; Jacobs PL; Keurentjes WJTM; King F; Lee CW; Lewen N; Marchant CA; Maris FA; Nye W; Powell S; Rockstroh H; Rutter L; Schweitzer M; Shannon E; Smallshaw L; Teasdale A; Thompson S; Wilkinson D
    J Pharm Sci; 2018 Sep; 107(9):2335-2340. PubMed ID: 29679706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxidative degradation of polysorbate surfactants studied by liquid chromatography-mass spectrometry.
    Borisov OV; Ji JA; Wang YJ
    J Pharm Sci; 2015 Mar; 104(3):1005-18. PubMed ID: 25581232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rational design to biologics development: The polysorbates point of view.
    Brovč EV; Mravljak J; Šink R; Pajk S
    Int J Pharm; 2020 May; 581():119285. PubMed ID: 32240804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification of Biopharmaceutically Relevant Nonionic Surfactant Excipients Using Benchtop qNMR.
    Lynch CC; Khirich G; Lee RT
    Anal Chem; 2024 Apr; 96(17):6746-6755. PubMed ID: 38632675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization and stability study of polysorbate 20 in therapeutic monoclonal antibody formulation by multidimensional ultrahigh-performance liquid chromatography-charged aerosol detection-mass spectrometry.
    Li Y; Hewitt D; Lentz YK; Ji JA; Zhang TY; Zhang K
    Anal Chem; 2014 May; 86(10):5150-7. PubMed ID: 24749737
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Industry Perspective on the Use and Characterization of Polysorbates for Biopharmaceutical Products Part 2: Survey Report on Control Strategy Preparing for the Future.
    Wuchner K; Yi L; Chery C; Nikels F; Junge F; Crotts G; Rinaldi G; Starkey JA; Bechtold-Peters K; Shuman M; Leiss M; Jahn M; Garidel P; de Ruiter R; Richer SM; Cao S; Peuker S; Huille S; Wang T; Brun VL
    J Pharm Sci; 2022 Nov; 111(11):2955-2967. PubMed ID: 36002077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80.
    Glücklich N; Dwivedi M; Carle S; Buske J; Mäder K; Garidel P
    Int J Pharm; 2020 Dec; 591():119934. PubMed ID: 33059015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.